Home > Boards > US Listed > Biotechs > Can-Fite BioPharma (CANF)

Can-Fite to Present its NASH Program in Fireside

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 126
Posts 26,036
Boards Moderated 7
Alias Born 02/07/04
160x600 placeholder
Can-Fite BioPharma (CANF) Receives a Buy from H.C. Wainwright TipRanks - 12/2/2021 10:45:27 AM
Can-Fite Biopharma reports 9M results Seeking Alpha - 11/26/2021 7:17:21 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/26/2021 7:10:06 AM
Can-Fite Reports Third Quarter 2021 Financial Results & Provides Clinical Update Business Wire - 11/26/2021 7:00:00 AM
Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021 Business Wire - 11/24/2021 7:00:00 AM
Can-Fite partner initiates piclidenoson study for canine osteoarthritis Seeking Alpha - 11/23/2021 7:36:56 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/23/2021 7:22:53 AM
Can-Fite’s Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis Business Wire - 11/23/2021 7:00:00 AM
Can-Fite to Present at H.C. Wainwright 7th Annual Israel Conference Business Wire - 11/12/2021 7:00:00 AM
Can-Fite’s Findings on Cannabis Compound’s Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLD’s The Liver Meeting® 2021 Conference Business Wire - 11/1/2021 7:00:00 AM
Can-Fite’s NASH Patents Granted and Allowed in Japan, Hong Kong, and Mexico Business Wire - 10/28/2021 7:00:00 AM
Can-Fite CEO to Present Namodenoson’s Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit Business Wire - 10/26/2021 7:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 10/21/2021 7:12:23 AM
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal Business Wire - 10/21/2021 7:00:00 AM
Can-Fite to Present at H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021 Business Wire - 10/5/2021 7:00:00 AM
Can-Fite CEO to Join Benzinga Medical Cannabis Panel and Deliver Company Presentation at Healthcare Small Cap Conference on September 29, 2021 Business Wire - 9/22/2021 7:00:00 AM
Can-Fite to Participate in Three Upcoming Pharma Partnering Conferences Business Wire - 9/17/2021 7:00:00 AM
Can-Fite to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Business Wire - 9/9/2021 7:00:00 AM
Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study Business Wire - 9/2/2021 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/2/2021 6:05:15 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 9/1/2021 4:31:26 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/1/2021 6:10:34 AM
Securities Registration (foreign Private Issuer) (f-1) Edgar (US Regulatory) - 8/26/2021 4:32:22 PM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 8/26/2021 4:31:32 PM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 8/26/2021 4:31:26 PM
midastouch017   Monday, 11/09/20 08:41:10 AM
Re: None
Post # of 1727 
Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020


Mon, November 9, 2020, 2:00 PM GMT+2

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the Company’s CEO Dr. Pnina Fishman will present at the H.C. Wainwright 6th Annual Israel Conference in a virtual fireside chat format during the Healthcare session on Thursday, November 12, 2020 from 1:00 PM to 1:30 PM ET. Dr. Fishman’s chat will focus on Can-Fite’s Namodenoson in the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

In a Phase II NASH/NAFLD study that successfully achieved its endpoints, Namodenoson at the 25 mg dose produced statistically significant results showing anti-inflammatory, anti-steatotic, and anti-fibrosis effects in the liver, while also having a strong safety profile and being well tolerated. The NASH market is projected to reach at least $35 billion by 2025. There are currently no other treatment options approved for this growing unmet need.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences